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INTRODUCTION
The epipodophyllotoxins, Etoposide (VP-16) and
Teniposide, are useful antineoplastic agents with ac-
tivity in both hematologicmalignancies andsolid tumors
(1). The anticancer activity of these agents is thought
to result at least in part from stabilization of the cleav-
able complex, an intermediate in which topoisomerase
 is covalently bound to DNA in a step that precedes
DNA religation (2). Thismechanismof action is shared
by other antitumor agents including the anthracyclines,
the aminoacridines, and the ellipticines(3).
The efficacy of topoisomeraseinhibitors (epipo-
dophyllotoxins, aminoacridine, and mitoxantrone) is
limited by the occurrence of drug resistance in the tu-
mor cell population. Cellular insensitivity to drugs that
stabilize the cleavable complex is frequently expressed
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as multidrug resistance (MDR)(4). In some cell lines,
overexpression of MDR-1/P-glycoprotein or the
multidrug resistance associated protein (MRP)1, has
been demonstrated and implicated as themechanism
of resistance (5, 6). These proteins are known to confer
multidrug resistant phenotypes to the cancer cells.
Although the primary structures of P-glycoprotein
and MRP share only 15% amino acid homology (7),
both P-glycoprotein and MRP are involved in drug
resistance to a similar profile of chemotherapeutic
agents that include anthracyclines, vinka alkaloid, and
epipodophyllotoxins (8). Another transporter, termed
breast cancer-resistance protein (BCRP), also known
as mitoxantrone-resistance protein and placenta ATP
binding cassette (ABC) protein, was described in breast
and colon carcinoma cell lines selected for higher-level
resistance to the antineoplastic drug, mitoxantrone.
Typically, these cells have reduceddrug accumulation,
secondary to increased drug efflux. Recently, the cDNA
of a new ABC superfamily,MRP2 has been isolated (9).
The size of MRP2 mRNA was estimated to be about
6.5 KB(10), similar to that ofMRP1mRNAbut larger
than the human MDR-1 mRNA(4.5 KB).
Usinga single clone selectionprocess,we successfully
isolated and characterized three human glioma cell
lines isolated for their resistance toamsacrine (mAMSA)
or VP-16, T98G-m1, T98G-m2, and gli36-VP1, which
overexpress MRP2 but do not expressMRP1-5 except
2 andMDR-1.We herein discuss a possible correlation
between MRP2 and the cellular VP-16 accumulation.
MATERIALS AND METHODS
Cell Lines and Cell Cultures
The cell lines described in the present report were
initially isolated as single clones. Four parental glioma
cell lines were used : T98G, Gli36, U87, and SNB19.
The selections were performed at different drug con-
centrations for each cell line (T98G:300nM VP-16
or 30 nM mAMSA ; Gli 36 : 300 nM VP-16 or 50 nM
mAMSA ; U87 : 500nMVP-16 or 50nMmAMSA ; and
SNB 19 : 500nMVP-16 or 50nMmAMSA). These con-
centrations were those that were toxic to most cells
(IC 99), and resulted in the survival of only a few cells
that grew as isolated clones. 50Clones were picked
as single colonies and subsequently, a population of
cells from each concentration of the drugswasmain-
tained in the same concentration of which was used
in the selection. After a single clone selection process,
we have characterized 50 human glioma cell lines by
the Northern analysis with probes of Topoisomerase
α, MRP1-5, BCRP, andMDR-1. By understanding
the function ofMRP2, we picked up three drug resistant
sublines (T98G-m1, T98G-m2, and gli36-VP1) for
resistance tomAMSAor VP-16 that overexpressMRP
2, but do not overexpress MDR-1, BCRP, and MRP
1-5 except 2.
Transfection with the MRP2 Antisense Expression Vector
Exponentially growing the resistant cell lines and
the parental cell lines (5×106) were washed and placed
in serum-free medium. Amixture of 50µg of Lipofectin,
10µg of theMRP2 antisense expression vector (11), and
1 µg of pSV2-neo DNAwas added for 12h, after which
fresh medium was added. The cells were incubated in
the selection medium (i.e. containing 400µg/mlG418)
for 3-4 weeks. Three stable transfectants (T98G-m1-R,
T98G-m 2-R, and Gli 36-VP 1-R), which also showed
reduced cellular MRP2 levels, were selected among
the G418-resistant clones.
Cytotoxicity Assays
Cytotoxicity assays were performed as previously
described (10,12). Briefly, 300 to 1000 cells/well plated
in 96-well dishes were incubated overnight after which
time drug was added and the cells were incubated for
an additional 5 days. At the endof the incubationperiod,
cells were fixed with trichloroacetic acid, and stained
with 0.4% sulforhodamine B dissolved in acetic acid.
Unbound dye was removed bywashing four times with
1% acetic acid, and protein bound dye was extracted
with 10mM unbuffered Tris base. Optical density was
determined on a 96-wellmicrotiter plate readerbymeas-
uring the OD at 570nm. The cytotoxic effects of the
drugs were expressedquantitatively as thedose required
to kill 50% of the cells (IC50). Each experimental group
consisted of six independent wells.
Cloning of topoisomerase IIα, MRP1-5, MDR-1, and
BCRP cDNA by Reverse Transcription-PCR
Synthetic oligonucleotides corresponding to the pub-
lished cDNA sequence of humanMRP1-5 were used
to isolate by RT-PCR specific products for direct cloning
into pGEM-3z vectors (Promega, Madison, WI). The
identity of the cDNA clones was confirmed by direct
sequence analysis prior to their use as probes for north-
ern analysis. The sequences of the oligonucleotides
used in the RT-PCR were as follows : topoisomerase
IIα : -915 ‘TGTGGAGAAGCGGCTTGGTC3’ and 449 5
‘TAGTTACTAGAAGTTAGGAGCT3’;MRP1:733 5
‘CGGAAACCATCCACGACCCTAATCC3’ and 1027 5
‘ACCTCCTCATTCGCATCCACCTTGG 3’ ; MRP2 :
41365 ‘CTGCCTCTTCAGAATCTTAG’ and 4376 5
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‘CCCAAGTTGCAGGCTGGCC’ ; MRP3 : 5‘GATAC
GCTCGCCACAGTCC3’ and 5 ‘CAGTTGGCCGTG
ATGTggCTG 3’ ; MRP 4 : 5 ‘CCATTGAAGATCTT
CCTGG 3’ and 5‘GGTGTTCAATCTGTGTGC 3’ ;
MRP 5 : 5 ‘GGATAACTTCTCAGTGGG 3’ and 5‘G
GAATGGCAATGCTCTAAAG 3’ ; MDR-1 : 3525‘C
AGTGTTTGCCATAGTATTTTCAAGGATTG 3’an
d 7415‘CCCTTTAACACTAGAAGCATCAC 3’ ;
BCRP : 19795‘TGCCCAGGACTCAATGCAACAG’
and 25405‘GACTGAAGGGCTACTAACC 3’.
Northern Blotting
Total RNA (20µg/lane) separated on a 6% formal-
dehyde gel and transferred to Hybond N＋ with 10X
SSC. The membranes were hybridized at 42℃over-
night with the radiolabeled probe inHybrisol I (Oncor,
Gaithersburg, MD)(13). We used the RNA of ZR-VP
13 cells that overexpressed all drug resistant genes
(MDR-1, MRP1-5, topoisomeraseⅡα, and BCRP) as
positive control(14).
Immunoblotting
Immunoblotting for theMRP2 proteinwas performed
using detergent-solubilizedmembraneproteins resolved
on a 6% SDS-polyacrylamide. Immunoblottingwas per-
formed with a 1:2000 dilution of a monoclonal MRP
antibody (cosmobio, Tokyo, Japan).After threewashes
in TBS-T, the membranes were incubated with HRP-
conjugated anti-mouse secondary antibody at a dilution
of 1 : 1000 for 1 hr. Five washes were then performed
and immunolabeled protein was detected by chemi-
luminescence (15).
Preparation of crude nuclear extracts
Crude nuclear extracts were prepared from 1×108
cells in early log phase culture as previously described
(15). Briefly, cells washed 3 times with ice-cold PBS,
were harvested with a rubber scraper, and collected
by centrifugation. Cell pellets were then lysed in10
nM Tris-HCl (pH 7.5), 1.5 mM MgCl2, 10 nM NaCl,
and 1% Nonidet P-40. Nuclei were isolated by centrifu-
gation at600 X g for10min, suspended in 2ml of 50
mM Tris-HCl (pH7.5), 25mM KCl, 2mMCaCl2, 5mM
MgCl2 buffer, and layered over a 0.6 ml cushion of
the suspension buffer containing 0.6M sucrose. Fol-
lowing centrifugation at 2000X g for10min, the nu-
clear pellets were resuspended in 0.2ml of 50mMTris-
HCl (pH7.5), 25mM KCl, 5mMMgCl2 ;and20µl of
0.2 M EDTA (pH8.0) was added followed by 2 volumes
of 80mM Tris-HCl (pH7.5), 1mM dithiothreitol, 2mM
EDTA, 0.53M NaCl, and 20% glycerol ; the final con-
centration of NaCl was 0.35M. Extraction then pro-
ceeded on ice for 60 min. Protein concentration of the
extracts was determined by the method of Bradford.
DNA topoisomerase II activity assay
The standard reaction contained 50mM Tris-HCl
(pH 7.5), 85mM KCl, 10mMMgCl2, 5mM dithiothre-
itol, 0.5mMEDTA, 0.03mg/ml bovine serum albumin,
and 1mM adenosine triphosphate. The decatenation
reaction of catenationDNAwas carried out with serial
dilutions of nuclear extract and 0.1µg of kinetoplast
DNA (TopoGEN, Columbus, Ohio) in a final volume
of 20 µl at 30℃ for 30 min. The reaction was termi-
nated by adding 2µl of 1.2mg/ml proteinase K in 22
mM EDTA followed by incubation for15 min. at 37℃.
Then, 5ml of 0.05% bromophenol blue in 50% glycerol
was added to the reactionmixture. Samples were sepa-
rated by electrophoresis through a 1% agarose gel. After
staining with ethidiumbromide, gelswerephotographed
under UV illumination (15).
Cellular Accumulation and Efflux Assay for[3H]-VP-16
3.5×105 cells were plated in each well of a six-well
plate and incubated for 24hr at 37℃. Growth medium
was then replaced with serum-freeMEM, and the cells
were incubatedwith 2.6µM[3H]-VP16 for various times
up to 45 min. at 37℃. At the completion of the incu-
bation period, cells were quickly washed three times
with ice-cold PBS, lysed with 2ml of 0.05% SDS, and
mixed with 3 ml of Scintisol. For efflux studies, cells
plated as for accumulation assays were incubatedwith
2.6 M[3H]-VP-16 for 45 mins then washed free of ex-
tracellular VP-16 by rinsing with ice-cold PBS. Cells
were incubated in VP-16-free medium at 37℃. Then
over a 30 min period, the levels of intracellular radio-
activity were measured(15).
Statistical analysis
All cytotoxicity assays (MRP2 expressing cells versus
parental cells) were analyzed by two-way analysis of
variance (ANOVA)(n=6), with differences between
individual means determined by Bonferroni’s post-
tests. In accumulation and efflux tests, each point
represents the means±SD of independent six experi-
ments (differenceswere considered statically significant
(P＜0.05) in MRP2 expressing resistant cells or their
MRP 2 antisense transfectants versus parental cells).
RESULTS
Cytotoxicity assays
Table1 depicts the cross-resistance profiles of the
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three drug resistant sublines (T98G-m1, T98G-m2,
and Gli36-VP1)and their transfectants (T98G-m1-R,
T98G-m2-R, and Gli36-VP1-R) to various chemothera-
peutic agents. Cross-resistance to four topoisomeraseⅡ
poisons(p<0.05) (VP-16, mAMSA,mitoxantrone, adria-
mycin) was observed in these drug resistant cells with
little cross resistance to the microtubule active agent,
vincristine. The transfectants displayed enhanced sen-
sitivities to topoisomeraseⅡinhibitors, VP-16,mAMSA,
mitoxantrone, and adriamycin.
Expression of mRNA of drug resistance genes
We examined the expressions of topoisomerase IIα,
MRP 1-5, BCRP, andMDR-1, and the results are shown
in Fig.1. The Northern blot analysis showed that these
resistant cells overexpressedMRP2, but did not over-
express MDR-1 or MRP1-5 except 2. Moreover, in the
results of the Northern blot analysis of mRNA for
topoisomerase Ⅱα identical results were observed in
the parental cell lines and their resistant cell lines.
TopoisomeraseⅡactivity
When the topoisomeraseⅡactivity was measured
in decatenation assays using crude nuclear extracts,
similar levels of activity were observed in the crude
nuclear extracts of resistant cell lines (Gli36-VP1, T98
G-m 1, and T98G-m 2 cells) and their parental cells,
suggesting that alterations in topoisomeraseⅡdid not
account for the resistance in these cells (Fig.2).
Immunoblotting
By immunoblotting with polyclonal antibody against
the human MRP2, we demonstrated the presence of
a Mr 200,000MRP2 protein in the resistant cell lines
(densitometry quantitation : T98G-m1, 17times of the
parental T 98G ;T98G-m2, 125 times ; and Gli 36-VP
Table 1. Cross-resistance profiles of the three drug resistant sublines
VP-16 mAMSA Mitoxantrone Adriamycin Vincristine
a) IC50Gli 36
Gli36-VP1
b) relative resistance
Gli36-VP1-R
b) relative resistance
a) IC50T98G
T98G-m1
b) relative resistance
T98G-m1-R
b) relative resistance
T98G-m2
b) relative resistance
T98G-m2-R
b) relative resistance
48.7±4.0
6234±118
128c)
54.7±7.3
1.1
5.1±1.9
398±226
78c)
6.3±1.5
1.2
833±139
163c)
7.9±2.1
1.5
2.4±0.4
48.0±20.2
20c)
3.5±1.1
1.5
0.6±0.44
10.8±3.8
18c)
0.8±0.32
1.3
17±1.3
28c)
0.7±0.86
1.2
0.11±0.09
0.528±0.44
4.8c)
0.18±0.11
1.6
0.023±0.02
0.13±0.05
5.7c)
0.031±0.05
1.3
0.12±0.02
5.2c)
0.026±0.10
1.1
0.42±0.12
1.7±0.6
4.0c)
0.63±0.18
1.5
2.0±0.5
6.6±5.7
3.3c)
2.5±0.3
1.3
9.0±2.3
4.5c)
3.4±1.2
1.7
4.2±0.95
3.9±0.36
0.93
4.5±1.32
1.1
0.7±0.1
1.3±0.08
1.9
1.1±0.3
1.6
0.7±0.1
1.0
1.2±0.4
1.7
Each experimental group consisted of six independent wells
a) IC50 : The cytotoxic effects of the drugs were expressed quantitatively as the dose required
to kill 50% of the cells (ng/ml)
b) relative resistance ; ratio of IC50 of the individual cell lines
c) Significant different (p<0.05) from their parental cell lines
Figure 1 Northern blot analysis of topoisomerase IIα(4.5
KB), MRP 1-5(4.5 KB, 4.4 KB, 4.7 KB, 4.3 KB, 6.5 KB), MDR-1
(4.5 KB), and BCRP (2.8 KB) expression in the drug resistant
sublines and their parental cell lines. β-actin was used as internal
control.
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1, 78times of the parental Gli36)(Fig 3). To determine
whether the cellular sensitivity to the anticancer agents
was closely associated with the cellular levels ofMRP2,
we established cell lines with the same levels ofMRP2
as their parental cells by introducing the MRP 2 an-
tisense expression plasmid into the resistant cell lines.
As compared with the parental cell lines, the resistant
cell lines transfected withMRP2 antisense cDNA had
decreased to the same levels ofMRP2 as their parental
cells (densitometry quantitation : T98G-m1-R, 1.1times
of the parental T98G;T98G-m2-R, 1.4times;and Gli
36-VP 1-R, 1.5 times of the parental Gli 36)(Fig 3).
VP-16 accumulation and efflux
VP-16 accumulation and efflux studies were carried
out in the parental cell lines and their drug resistant
sublines (Fig.4). Figure 2A and 2C of demonstrate the
3H-VP-16 accumulation in the parental cells and the drug
resistant sublines. VP-16 accumulation over 45min is
displayed as pmol of VP-16/107 cells. 3H-VP-16 accumu-
Figure 2 VP-16 accumulation and efflux studies were carried out in the parental cell lines and their drug resistant
sublines. A) and C) demonstrate the 3H-VP-16 accumulation in the parental cells and the drug resistant sublines.
Accumulation over 45 min period is displayed as p mol of VP-16/107 cells. 3H-VP-16 accumulations for the resistant
sublines relative to the parental cells were T98G-m1, 76% (T98G:42.0±9.0, T98G-m1:31.9±4.3, p<0.05);T98G-m2,
48%(T98G:42.0±9.0, T98G-m2:20.2±3.8, p<0.05) and Gli36-VP1, 58%(Gli36:41.1±3.7, Gli36-VP1:20.2±3.8,p<0.05).
Increased accumulation was observed in the three sublines transfected with the MRP 2 antisense cDNA, with partial
restoration of levels to that of the parental cells (T98G-m1-R, 96%of the parental T98G ;T98G-m2-R, 98% ;and Gli36-
VP1-R, 94%of the parental Gli36). B) and D) demonstrates the 3H-VP-16 present in the drug resistant cells, compared
to the efflux present in parental cells. Relative to the amount of 3H-VP-16 present following loading, the proportion of
3H-VP-16 remaining after 45 min. of efflux in the T98G-m1, T98G-m2, and gli36-VP1 were 41%, 33%, and 34%, compared
to 49%, and 48% in their parental cells respectively. As compared with the resistant cells, cellular efflux levels of VP-16
were increased in the transfectants and their parental cells (T98G-m1-R, 96%of the parental T98G;T98G-m2-R, 96%;
and Gli 36-VP 1-R, 93% of the parental Gli 36). Each experimental group consisted of six independent wells.
＊significantly different (p<0.05) between the resistant cell lines and their parental cell lines (incubation time at 45 min).
＊＊significantly different (p<0.05) between the resistant cell lines and their own transfected MRP2 antisense cDNA
(incubation time at 45 min)
A), B) : ■ ; T98G, ▲ ; T98G-m1, ● ; T98G-m2, ◆ ; T98G-m1-R, ◇ ; T98G-m2-R
C), D) : ★ ; Gli36, ▼ ; Gli36-VP1, △ ; Gli36-VP1-R
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lations for the resistant sublines relative to the parental
cells were T98G-m1, 76%(T98G : 42.0±9.0, T98G-m1 :
31.9±4.3, p<0.05) ;T98G-m2, 48%(T98G:42.0±9.0,
T98G-m2:20.2±3.8, p<0.05) and gli36-VP1, 58%(Gli
36 :41.1±3.7, Gli36-VP1:20.2±3.8, p<0.05). Increased
accumulation was observed in the three sublines trans-
fected with MRP2 antisense cDNA, with partial res-
toration of the levels to that of the parental cells (T98
G-m1-R, 96% of the parental T98G;T98G-m2-R, 98%;
and Gli36-VP-R, 94% of the parental Gli36). Figure 2B
and 2D demonstrate the 3H-VP-16 present in the drug
resistant cells, as compared to the efflux present in
the parental cells. Relative to the amount of 3H-VP-16
present following loading, the proportion of 3H-VP-16
remaining at 45 min. of efflux in the T98G-m1, T98
G-m 2, and Gli 36-VP 1were 41±6.1%, 33±0.91%, and
34±4.6%, as compared to 49±3.1% (T98G) and 48±1.2%
(Gli 36) in their parental cells respectively. We also
determined whether the reduced cellular levels ofMRP
affected the cellular accumulationofdrugs.As compared
with the resistant cells, the cellular efflux levels of VP-
16 increased in the transfectants and their parental cells
(T98G-m1-R, 96%of the parental T98G ;T98G-m2-
R, 96% ; and Gli 36-VP-R, 93% of the parental Gli 36).
DISCUSSION
In the early studies, it was recognized that resistance
to the structurally unrelated natural products and de-
creased drug accumulation were the hallmarks of the
phenotype that we now associate with overexpression
of MDR-1(16). Approximately 20 years later, a second
ATP-dependent transporter, MRP1 was linked with
MDR. MRP1-overexpressing cells are primarily re-
sistant to VP-16and doxorubicin (5,17). In addition to
MRP 1, other genes of theMRP family (MRP2-5) were
isolated. Of theseMRP family genes,MRP1 and 3were
expressed in the human glioma cell lines and clinical
glioma specimens. However, unlikeMRP1, expressions
of the MRP 2 and 3 have not been detected in the nor-
mal brain tissue(11, 20-21). For understanding the func-
tion of MRP2 in this study, we isolated 50 sublines by
exposures to VP-16 or mAMSA and picked up three
drug resistant sublines (T98G-m1, T98G-m2, and gli
36-VP1) that overexpressed MRP2, but did not over-
express MDR-1,BCRP, andMRP1-5except2.Theresults
of 50 sublines described in the present study (data not
Figure 3 Immunoblotting analysis forMRP2 in the drug resistant
cell lines and their parental cell lines. By immunoblotting with the
polyclonal antibody against human MRP2, we demonstrated the
presence of a Mr200,000 MRP2 protein in the resistant cell lines.
To determine whether the cellular sensitivities to anticancer agents
were closely correlated with the cellular levels of the MRP2, we
established the cell lines with reduced levels of theMRP2 by in-
troducing the MRP2 antisense expression plasmid into the resis-
tant cell lines. As compared with the parental cell lines, the resis-
tant cell lines transfected withMRP2 antisense cDNA had the same
levels of MRP 2 as their parental cells.
Figure 4 Decatenation of kinetoplast DNA by nuclear extract. In the absence of nuclear extract, the catenated kinetoplast
DNA remains in the gel. Comparable topoisomerase activity is demonstrated by comparable decatenation of kinetoplast
DNA to the monomer minicircles, using increasing amounts of the nuclear extracts.
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shown) support and extend previous observations. The
initial change observedwas a decrease in the expression
and activity of topoisomeraseⅡα. Previous studies have
documented reduced expression of topoisomerase
Ⅱ with drug selection, and this has been proposed as
a mechanism of drug resistance(22-24). In our own
experience, we have found decreased expression of
topoisomerase Ⅱα (less than 50% of parental cells) in
39 of 50 isolates, suggesting that reduced expression
is a common adaptation. Reduction of topoisomerase
levels effectively diminishes the main intracellular
target of VP-16 and other topoisomerase poisons and
can confer broad cross-resistance to these agents(25).
Although in some cell lines, topoisomeraseⅡα ex-
pression was partially maintained with resistance to
topoisomerase Ⅱ poisons, as a results of increased ex-
pression of drug efflux pump [MRP1(33/50), MRP2
(28/50), MRP3(12/50), MRP4(0/50), MRP5(0/50),
MDR 1(6/50), and BCRP(7/50)]. The three cell lines
are resistant to topoisomeraseⅡ inhibitors (VP-16,
mAMSA, mitoxantrone andAdriamycin) with little cross
resistance to themicrotubule active agent, vincristine.
This resistance is not due toMDR-1, BCRP, andMRP
1-5 except 2 overexpression, as demonstrated by the
Northern blot analysis and VP-16 accumulation and
efflux studies. Especially in the three cell lines composed
of T98G parental cells and theirmAMSA-selectedMRP
2-expressing sublines,wenoticedahighcorrelationbe-
tweenMRP2mRNAoverexpressionandcross-resistance
to topoisomeraseinhibitors, suggesting that MRP2
could be a new transporter and a new drug resistant
mechanism for topoisomeraseinhibitors. To deter-
mine whether the cellular sensitivity to anticancer agents
closely correlated with the cellular levels ofMRP2, we
established cell lines with reduced levels of MRP2 by
introducing the MRP2 antisense expression plasmid
into the resistant cells and their parental cells.We found
that the resistant cells transfectedwithMRP2 antisense
cDNA displayed increased cellular levels of VP-16 and
enhanced sensitivities to topoisomeraseⅡinhibitors,
VP-16, mAMSA, mitoxantrone, and Adriamycin (26).
We also found that resistant cell lines transfected with
MRP2 antisense cDNA displayed an enhanced sen-
sitivity to topoisomeraseⅡinhibitors (VP-16,mAMSA,
mitoxantrone, and adriamycin). It has also been shown
that cells transfected withMRP1cDNA aswell as drug-
selected MRP1-overproducing cells acquired resis-
tance to VP-16, adriamycin, and vincristine but not to
camptothecin-11 and cisplatin. Thus, MRP2 appears
to modulate the sensitivity to certain anticancer agents
as MRP 1(27).
In contrast, a recent study has demonstrated that
the expression of MRP2 is increased in the colorectal
cancers as compared with non-cancerous tissues and
also that the drug sensitivity to cisplatin closely correlated
with theMRPmRNA levels in the colorectal cancers
(28). Another study demonstrated that antisenseMRP2
cDNA transfectants could increase the sensitivity to
cisplatin. Like the MRP1, MRP2 protein appears to
show strong affinities to glutathione and its conjugates.
Further studies are necessary to determine whether
MRP2 is directly involved in the sensitivity to VP-16, in
addition to cisplatin, with or without glutathione or
glucuronide (11).
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